ACI’s 18th Annual Rx Drug Pricing Master Class

Litigation-healthcare partner Andy Ruskin will present on a panel titled “Overcoming New and Evolving Challenges in the Pricing of Specialty Products” at the ACI’s 18th Annual Rx Drug Pricing Master Class.

Topics will include:

• What qualifies as a specialty pharmaceutical, and how are they different from other drugs?
• What are some of the factors considered when pricing a specialty product?
• Evaluating the EpiPen hearings and their impact on pricing
• The impact of Trump’s White Paper and any implementation thereof on SP products
• Adhering to HRSA’s 340B requirements with respect to limited distribution drugs
• Choosing a specialty pharmacy distribution chain, a buy and bill distribution chain, or both
• Rules regarding “bridge” programs
• What are the pricing and contracting compliance issues that exist in personalized medicine and gene therapies?
• Discussing bills at the federal and state levels in relation to opioids
  • What theories are states using against opioid manufacturers that effect pricing?
  • The recent tax in New York on opioids within the state
  • What other states are planning to tax the product?
• Exploring the rising prices on opioid inhibiting drugs
• What are the evolving pricing risks going forward?